• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Endologix shares dip on Q2 loss of $27.1 million

Endologix shares dip on Q2 loss of $27.1 million

August 9, 2019 By Nancy Crotti

EndologixShares in Endologix (NSDQ:ELGX) slipped by 8% to $6.06 apiece in midday trading today following yesterday’s second-quarter results that beat The Street on earnings expectations and sales.

The Irvine, Calif.-based company reported a net loss of $27.1 million or -$1.50 per share on sales of $36.24 million for the three months ended June 30, 2019, for a loss of 13.6% on sales that fell by 19% compared with Q2 2019. 

Adjusted to exclude one-time items, earnings per share were –$0.37, 43¢ ahead of The Street, where analysts were looking for sales of $36.09 million.

“We are pleased with our second-quarter results, as stronger execution led to a sequential improvement in revenue,” said CEO John Onopchenko in a news release. “Our culture of accountability is yielding tangible results, and our team continues to steadily leverage a growing body of clinical evidence to rebuild credibility in the marketplace. We are excited about the progress we made during the first half of the year against both our near- and long-term targets, providing us confidence in our full-year outlook. We will remain focused on execution as we continue to take meaningful and necessary steps to position the Company for sustainable long-term success.”

EU notifying body GMED reinstated the CE Mark for Endologix’s Nellix stent graft system in June, following a suspension in January triggered by a halt to unrestricted sales of the stent grafts and a voluntary recall of all existing inventory. Nellix was designed for treating abdominal aortic aneurysms.

Nellix is only approved as an investigational device in the United States. The company’s Ovation Alto system is only approved as an investigational device and is not currently approved in any market.

In other news, the FDA yesterday gave Endologix an IDE exemption approval to begin a pivotal study on its Nellix Chimney endovascular aneurysm sealing device (ChEVAS) system. CheVAS was designed to combine the Nellix 3.5 endograft with parallel visceral stents to enable treatment of patients with juxta-renal, para-renal, and suprarenal abdominal aortic aneurysm.

The company also announced that it has named Boston Scientific (NYSE:BSX) its exclusive distributor in China.

“China is one of the largest and fastest-growing EVAR markets in the world, representing an exciting market opportunity for Endologix,” Onopchenko said in a separate news release. We look forward to building our brand in this important market by leveraging the Boston Scientific team’s extensive experience introducing new products for patients suffering from vascular disease.”

Endologix reaffirmed its previously issued annual guidance and continues to expect 2019 sales of at least $140 million. The company anticipates Q3 2019 sales of $35 million to $37 million and continues to expect full-year operating expenses of $130 million to $140 million.

The current consensus EPS estimate is -$0.72 on $34.31 million in sales for the Q3 2019 coming quarter and -$3.23 on $142.24 million in sales for the current fiscal year, according to a report by Zacks.

Filed Under: Blog, Business/Financial News, News Well, Wall Street Beat Tagged With: Endologix

More recent news

  • Presidio wins FDA IDE for ultra-low frequency neuromod, hires new CFO
  • Epiminder study backs implantable EEG tech
  • Neurent Medical wins FDA nod for next-gen chronic rhinitis treatment
  • Medtronic unveils “MiniMed” as name for soon-to-be separated Diabetes unit
  • Medtronic issues safety notice for Hugo surgical robot console in Europe

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy